ArticleCureus2025
Estimation of Cardiac Troponin-T Levels in Acute Myocardial Infarction With Reference to Short-Term Prognosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to estimate the cardiac troponin-T (cTnT) levels in patients with acute myocardial infarction (AMI) to measure the short-term prognosis.
methodSixty patients with symptoms of AMI within six hours of onset were included, and the prognostic significance of cTnT levels was evaluated to predict mortality, recurrent ischemic events, and heart failure. The diagnostic performance of cTnT was evaluated through sensitivity and specificity analysis based on the determined cut-off value. All participants underwent clinical evaluations, echocardiograms, and received thrombolytic therapy.
resultsAmong study participants, 45 patients were male (75%) and 15 were female (25%), and the mean age was 50.7±7.93 years. Cardiac troponin T was positive (cTnT >0.18 ng/mL) in 50 (83.34%) cases and negative in 10 (16.66%) cases. The mean cTnT levels were higher in patients who did not survive than those who did (2.92±1.43 vs 0.705±0.63 ng/mL). A cTnT levels between patients with and without recurrent angina shows a significant difference (1.9705±1.538 vs 0.82±0.915 ng/mL, p<0.001). A cTnT level of 0.22 ng/mL at presentation diagnosed AMI with a sensitivity of 76.92% and a negative predictive value (NPV) of 98.2%, and a specificity and positive predictive value (PPV) of 100% and 65.4%, respectively. A cut-off cTnT value of 2.2 ng/mL predicted mortality with a sensitivity of 76.92% and a negative predictive value (NPV) of 94%, and a specificity and positive predictive value (PPV) of 100% each. The multivariable analysis revealed several factors significantly associated with mortality: point-of-care cardiac troponin T ≥0.22 ng/mL (hazard ratio (HR): 1.95, 95% confidence interval (CI): 1.85-2.19), heart failure (HR: 1.85, 95% CI: 1.65-2.08), recurrent angina (HR: 1.38, 95% CI: 1.19-1.55), and reinfarction (HR: 1.04, 95% CI: 0.99-1.12).
conclusionCardiac troponin T positivity at admission consistently correlated with decreased rates of reperfusion after thrombolysis and lower ejection fraction. Cardiac troponin-T levels at admission can be able to predict the short-term prognosis, mortality, recurrent ischemic events, and heart failure in patients with AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.